Login to Your Account



BIO 2011

Corporate vs. Traditional VCs; Financing 'Options' Abound

By Jennifer Boggs


Thursday, June 30, 2011
WASHINGTON – A finance panel Tuesday afternoon on the evolution of the venture capital model in biotech turned briefly toward the rise of corporate venturing, a trend that has helped keep money flowing into private firms even in the economic downturn, though traditional VCs warn that those investments might come with a different set of strings attached.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription